Clinical, Histopathological, and Prognostic Characteristics of Patients with Prostate Cancer in Lubumbashi, Democratic Republic of Congo

Table 2

PSA level, prognostic features, and different treatment approaches of the patients.

Variable	Number (n = 88)	Percentage
PSA level at diagnosis
<10 ng/ml	11	12.50
10–100 ng/ml	48	54.55
>100 ng/ml	29	32.95
Mean (range)	133.7	(4–1564.5)
PSA level at 3 months of follow-up
<4 ng/ml	17	19.32
4–9.9 ng/ml	10	11.36
10–100 ng/ml	30	34.09
>100 ng/ml	31	35.23
Mean (range)	125.4	(0.16–1782.1)
Gleason score
<7	26	29.55
7	34	38.64
>7	28	31.82
D’Amico risk classification
Low risk	18	20.45
Intermediate risk	18	20.45
High risk	52	59.10
Treatment
Hormone therapy	66	75.00
Hormone therapy + pulpectomy	12	13.64
Surveillance	6	6.82
Radical prostatectomy	4	4.55
Outcome
Survived	50	56.82
Deceased	24	27.27
Lost to follow-up	14	15.91